RT Journal Article
SR Electronic
T1 Everolimus improves the efficacy of dasatinib in PDGFRα-driven glioma
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2019.12.28.19015974
DO 10.1101/2019.12.28.19015974
A1 Zachary Miklja
A1 Viveka Nand Yadav
A1 Rodrigo T. Cartaxo
A1 Ruby Siada
A1 Chase C. Thomas
A1 Jessica R. Cummings
A1 Brendan Mullan
A1 Stefanie Stallard
A1 Alyssa Paul
A1 Amy K. Bruzek
A1 Kyle Wierzbicki
A1 Tao Yang
A1 Taylor Garcia
A1 Ian Wolfe
A1 Marcia Leonard
A1 Patricia L. Robertson
A1 Hugh J.L. Garton
A1 Daniel R. Wahl
A1 Hemant Parmar
A1 Jann N. Sarkaria
A1 Cassie Kline
A1 Sabine Mueller
A1 Theodore Nicolaides
A1 Chana Glasser
A1 Sarah E.S. Leary
A1 Sriram Venneti
A1 Chandan Kumar-Sinha
A1 Arul M. Chinnaiyan
A1 Rajen Mody
A1 Manjunath P. Pai
A1 Timothy N. Phoenix
A1 Bernard L. Marini
A1 Carl Koschmann
YR 2020
UL http://medrxiv.org/content/early/2020/07/01/2019.12.28.19015974.abstract
AB Background Pediatric and adult high-grade glioma (HGG) frequently harbor PDGFRA alterations. We hypothesized that co-treatment with everolimus may improve the efficacy of dasatinib in PDGFRα-driven glioma through combinatorial synergism and increased tumor accumulation of dasatinib.Methods Dose response, synergism studies, P-gp inhibition and pharmacokinetic studies were performed on in vitro and in vivo human and mouse models of HGG. Six patients with recurrent PDGFRα-driven glioma were treated with dasatinib and everolimus.Results Dasatinib effectively inhibited the proliferation of mouse and human primary HGG cells with a variety of PDGFRA alterations. Dasatinib exhibited synergy with everolimus in the treatment of HGG cells at low nanomolar concentrations of both agents, with reduction in mTOR signaling that persists after dasatinib treatment alone. Prolonged exposure to everolimus significantly improved the CNS retention of dasatinib and extended survival of PPK tumor bearing mice. Pediatric patients (n=6) with glioma tolerated this combination without significant adverse events. Recurrent patients (n=4) demonstrated median overall survival of 8.5 months.Conclusion Efficacy of dasatinib treatment of PDGFRα-driven HGG is improved with everolimus and suggests a promising route for improving targeted therapy for this patient population.Trial Registration ClinicalTrials.gov NCT03352427Funding The authors thank the patients and their families for participation in this study. CK is supported by NIH/NINDS K08-NS099427-01, the University of Michigan Chad Carr Pediatric Brain Tumor Center, the Chad Tough Foundation, Hyundai Hope on Wheels, Catching up With Jack, Prayers from Maria Foundation, U CAN-CER VIVE FOUNDATION, Morgan Behen Golf Classic, and the DIPG Collaborative. The PEDS-MIONCOSEQ study was supported by grant 1UM1HG006508 from the National Institutes of Health Clinical Sequencing Exploratory Research Award (PI: Arul Chinnaiyan).Competing Interest StatementAMC is on the Scientific Advisory Board at Tempus.Clinical TrialNCT03352427Funding StatementThe authors thank the patients and their families for participation in this study. CK is supported by NIH/NINDS K08-NS099427-01, the University of Michigan Chad Carr Pediatric Brain Tumor Center, the Chad Tough Foundation, Hyundai Hope on Wheels, Catching up With Jack, Prayers from Maria Foundation, U CAN-CER VIVE FOUNDATION, Morgan Behen Golf Classic, and the DIPG Collaborative. The PEDS-MIONCOSEQ study was supported by grant 1UM1HG006508 from the National Institutes of Health Clinical Sequencing Exploratory Research Award (PI: Arul Chinnaiyan).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified human sequencing data will be made publically avilable according to established practices of University of Michigan MCTP/MiOncoseq practice.